Esperion Therapeutics Inc (ESPR) Stake Owned by Domain Parters Vii L P
Domain Parters Vii L P
disclosed that they own a 4.2% stake in Esperion Therapeutics Inc (NASDAQ:ESPR) in a Schedule 13D/A disclosure that was filed with the Securities and Exchange Commission on Monday, January 29th. The investor owns 1,101,080 shares of the stock worth approximately $80,819,272. The reporting parties listed on the disclosure included Domain Partners VII, LP, DP VII Associates, LP and Domain Associates, LLC. The filing is available through the SEC website at this link.
Shares of Esperion Therapeutics Inc (ESPR) traded down $1.48 during midday trading on Monday, reaching $73.40. 311,914 shares of the company’s stock traded hands, compared to its average volume of 580,531. Esperion Therapeutics Inc has a 1 year low of $10.82 and a 1 year high of $82.18. The firm has a market cap of $1,900.00, a PE ratio of -10.66 and a beta of 2.73.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.07). During the same quarter in the previous year, the business posted ($0.77) EPS. equities research analysts expect that Esperion Therapeutics Inc will post -7.3 earnings per share for the current fiscal year.
In other Esperion Therapeutics news, Director Nicole Vitullo sold 9,326 shares of the company’s stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total value of $502,205.10. Following the completion of the transaction, the director now directly owns 2,472 shares in the company, valued at approximately $133,117.20. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 32.50% of the company’s stock.
A number of research firms recently issued reports on ESPR. Stifel Nicolaus reiterated a “buy” rating and set a $70.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, October 4th. Needham & Company LLC upgraded shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and upped their price objective for the stock from $72.00 to $81.00 in a research report on Thursday, December 14th. Northland Securities reiterated a “buy” rating and set a $72.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, October 4th. BidaskClub upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, December 16th. Finally, Credit Suisse Group began coverage on shares of Esperion Therapeutics in a research report on Wednesday, January 17th. They set an “outperform” rating and a $103.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $77.23.
Esperion Therapeutics Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.